Wednesday, 17th November Clinical Oncology Society of Australia Annual Scientific Meeting 2021

Please join us for this breakfast symposium in the emerging field of Cardio- Oncology. Prof Bogda Koczwara will chair an exciting session of relevant case-based discussions, joined by a national panel of experts in the fields of oncology, cardiology and cardiooncology research. The symposium aims to highlight some of current challenges for cancer patients including risk stratification and mitigation across the age spectrum and breadth of treatment exposures, challenges in implementation of best practice guidelines as well as national research initiatives. The evolving role of this sub-speciality and how best to embed cardio-oncology services into clinical practice will be also highlighted.

Facilitators: Prof Bogda Koczwara AM, Dr Sarah Khan

Panel: A/Prof Eng-Siew Koh, A/Prof Rachel Conyers, Dr Aaron Sverdlov, A/Prof Joel Rhee, Prof Ray Chan

This conference acknowledges the sponsorship of 

Please join us for this breakfast symposium to discuss the recent advances in the treatment of metastatic urothelial carcinoma (UC) and the potential implications on the Australian treatment landscape. A/Prof Ben Tran will chair this session that aims to provide an overview of the current evidence and future treatment options for the management of metastatic UC. The evolving role of IO therapies and the use of chemotherapy will be discussed alongside Australian real-world registry data and local case studies.

Chairperson - A/Prof Ben Tran, Medical Oncologist, Peter MacCallum Cancer Centre
Speakers -

• Dr Carole Harris, Medical Oncologist, St George Hospital

• Dr Grace Kim, Medical Oncology Registrar, Peter MacCallum Cancer Centre

Title - Enhancing Geriatric Care in the Lung Cancer MDT
Time - 7:30am - 8:45am
Chairperson - Prof Meera Agar, Professor of Palliative Medicine, University of Technology Sydney & COSA Chair of Geriatric Oncology
Speakers -

• Dr Divyanshu Dua, Medical Oncologist - ICON Cancer Centre, Canberra
• Polly Dufton, Clinical Nurse Consultant, Lung - Austin Hospital, Melbourne
• Heather Lane, Geriatrician – Sir Charles Gairdner Hospital, Perth

Description - As the number of older cancer patients increases, the management of this group has become daily practice for most oncology teams. During this symposium, the speaker panel will:

• Discuss the impact of geriatrician involvement in the MDT on outcomes for patients with stage III unresectable NSCLC
• Share their perspective on what best practice looks like when caring for geriatric patients and
• Examine the tools available to clinicians and share insights into treatment and management considerations for the geriatric patient

• Medicinal cannabis for cancer patients – what are clinical trials telling us? - Peter Grimison
• Unsafe and unethical health care practices in the treatment of oncology patients: one Victorian regulator's experience. - Karen Cusack
• Doctor-Centred Care: An Outsider’s Experience of the Medical Profession through VAD - Andrew Denton

• Voluntary Assisted Dying (VAD): Data from Victoria, Internationally, and the Victorian Community of Practice Case Series - Cameron McLaren
• Early evidence from Victorian doctors at the voluntary assisted dying coalface - Lindy Willmott
• VAD and clinician identity two years on  - Camille La Brooy

12:00 PM Panel Discussion including VAD care navigators and Caroline Scott

• Cancer-related malnutrition and sarcopenia - Vickie Baracos
• Preventing Cancer-induced Muscle Loss Through Exercise and Nutrition - Robin Daly
• Nutrition research translation and practice innovations improve outcomes for patients with head and neck cancer - Judy Bauer
• Malnutrition, sarcopenia and frailty and association with multi-morbidity and mortality in UK Biobank participants with cancer - Nicole Kiss

• TBC - George Au-Yeung
• TBC - George Plunkett

Anna Galligan - Endocrine toxicity

• Association between patient-reported outcomes and survival in patients initiating first-line atezolizumab combination therapy for advanced non-small cell lung cancer (NSCLC) - Sarah Badaoui
• Alcohol intake trajectories during the life course and risk of alcohol-related cancer in a prospective cohort study - Harindra Jayasekara
• Gender representation in Australian academic Collaborative Cancer Clinical Trials Groups   - Vi Luong
• Exploring lower-limb symptoms and its relationship with lymphoedema, quality of life, anxiety and depression up to 2 years following gynaecological cancer - Melanie L Plinsinga
• Overall 5-year survival of breast cancer patients - the real life experience from linked data - Jesmin Shafiq
• Use of MADIP to gain insights into population groups with cancer - Alan Woods

• Exploring healthcare providers’ perspectives on psychosexual healthcare for LGBTIQ+ cancer survivors: A mixed-methods study - Sylvia Eugene Dit Rochesson
• SKILLED: A novel pathway to expanding clinical trial capacity - Christine Packer
• “What else can I do? I’ve tried my very best”: exploring the carer experience of supporting patients with nutrition care throughout treatment for head and neck cancer   - Bronwyn Segon
• Pandemic Professional Development: Challenges and successes of delivering a virtual oncology nutrition seminar - Belinda Steer
• Implementing a formal credentialing program to support pharmacy clinical trial competency in rural and regional hospitals - Steven Walker

Professor Michael Barton OAM

• Development of Psycho-oncology Telehealth Recommendations - Claire Cooper
• Improving telehealth accessibility during the COVID-19 pandemic in an Australian oncology outpatient service - Marissa Lam
• Perceptions of telehealth in real-world oncological care: An exploration of matched patient- and clinician- reported acceptability data from an Australian cancer centre - Sue-Anne McLachlan
• Transition to telehealth in a pandemic – experiences of Victorians affected by cancer - Victoria White

• The Role of Telehealth in Oncology Care: A Qualitative Analysis of Patient and Clinician Perspectives   - Eri Aung
• Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.   - Jayesh Desai
• Muscle mass, morbidity and mortality: A meta-analysis of the prognostic value of sarcopenia in patients head and neck cancer - Merran Findlay
• Cardiovascular health outcomes in a large population-based cohort of Australian women who have undergone therapy for invasive breast cancer: A Retrospective Review - Margot Lehman
• Clinical and biological correlates of immune-related adverse events - Mitchell S von Itzstein

• Budget impact modelling for listing new cancer treatments in different cancer stages using real-world data - Fanny Franchini
• Use of a radiological synoptic report to support multidisciplinary assessment of resectability in pancreatic ductal adenocarcinoma (PDAC).    - Anna Maciejewska and Nadia Ayres
• Bowel obstruction in advanced malignancies: An evaluation of patient outcomes at a Tertiary Cancer Centre - Harriet O'Rourke
• A dedicated Carcinoma of Unknown Primary clinic facilitates molecular analysis which is associated with improved overall survival outcomes - Arielle van Mourik

• Effectively communicating comprehensive tumour genomic profiling results: Mitigating uncertainty for advanced cancer patients - Nicci Bartley
• Caring for carers at discharge: Evaluation of an early intervention to assist carers of advanced cancer patients in transition from hospital to home. - Celia Marston
• The experiences of fear of cancer recurrence in carers: a qualitative systematic review and meta-synthesis - Kyra Webb
• The moderating role of social connectedness on the relationship between cancer caregiver burden and psychological outcomes - Eva Yuen

• Outcomes of Extensive-Stage Extrapulmonary Small Cell Cancer - Geovanny Gandy
• Addition of radiosensitising chemotherapy to peptide receptor radionuclide therapy (PRRT) in neuroendocrine neoplasms (NENs): a systematic review - Aran L Kanagaratnam
• The use of neoadjuvant systemic therapy in early breast cancer as a guide to locoregional therapies: A single institution review - Jessica McKie
• Psychological outcomes in advanced cancer patients after receiving genomic tumour profiling results - Sabina Vatter

• Caregiving in the context of immunotherapy: Emerging evidence - Afaf Girgis
• Navigating complex clinical conversations in the changing landscape of immunotherapy - Peter Martin
• Long term responders to immunotherapy and targeted therapy: laying the tracks as the train is coming - Julia Lai-Kwon
• Fear of cancer recurrence in people treated with immunotherapies  - Fiona Lynch

• The Molecular Screening and Therapeutics (MoST) Study: and Australian precision oncology platform - David Thomas
• Delivering personalized care and research for rare cancers in the increasingly genomic world - Clare L Scott
• BRCA testing and prostate cancer - Shaneen Sandhu

• How evidence-based models of treatment needs and costs can inform policy - Brooke Wilson
• Demand and Workforce Requirements for Optimal Use of Global Cancer Surgery - Sathira Perera
• Global Oncology in the Covid Era – Challenges and Opportunities - Gary Mckay
• The importance of National Cancer Control Plans for global cancer control - Mei Ling Yap
• Australia and New Zealand’s responsibilities in improving oncology services in the Asia-Pacific: A call to action - Brooke Wilson

• Get FACTSinated – information and communication during a pandemic - Amanda Piper
• iHeard – cancer questions answered “Does sugar cause cancer? Is it true only people who smoke get lung cancer?” - Jane Roy
• Regulating health information - free speech and public health, can we have both? - Hayley Jones

4:15 PM Panel Discussion

• Changes in distress and the number and types of problems reported by patients with cancer when routine distress screening was integrated within cancer services - Mona Faris
• E-supportive care screening tool pilot: meeting the needs of radiotherapy patients - Tara Gannon
• Priority Recommendations for the Implementation of Patient Reported Outcomes in Clinical Cancer Care: A Delphi study - Carolyn Mazariego
• Using Patient Reported Outcome Measures to improve multi-disciplinary symptom management - Natasha Roberts
• Implementing Patient Reported Outcome Measures (PROMS) in a multidisciplinary cancer survivorship clinical setting - Sim Yee (Cindy) Tan
• The impact of remotely completed real-time Patient Reported Outcome Measures (PROMs) on Emergency Department presentations - Kate Webber

This year we mark 10 years since the approval of the first immunotherapy – ipilimumab for advanced melanoma in Australia. Since then, there have been a number of advances in the cancer immunotherapy landscape that have improved patient outcomes across a number of cancer types1.

In this symposium we aim to explore the impact of immunotherapy and combination immunotherapy on patient outcomes in Australia (Melanoma, Renal Cell Carcinoma, Lung Cancer and Mesothelioma) and discuss the issues impacting patient survivorship after treatment.

Chair - Prof Nick Pavlakis - Medical Oncologist, Senior Staff Specialist, Department of Medical Oncology, Royal North Shore Hospital, and Genesis Care, NSW

Speakers -

• Dr Oliver Klein - Medical Oncologist, Olivia Newton John Cancer Research Institute, VIC

• Dr Megan Lyle - Medical Oncologist, Liz Plummer Care Centre at Cairns Hospital, Response Oncology and Cairns Private Hospital, QLD

• Dr Anthony Linton - Medical Oncologist, Concord Cancer Centre, NSW

• Mr David Grainger - Advisor & Board Chair – Biointelect

• Prof Michael Jefford – Medical Oncologist & Director of the Australian Cancer Survivorship Centre – Peter MacCallum Cancer Centre